{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:23:53Z","timestamp":1793413433096,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009448","name":"Universit\u00e0 degli Studi della Campania Luigi Vanvitelli","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009448","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Ocrelizumab (OCR) is a humanized anti-CD20 monoclonal antibody approved for multiple sclerosis (MS). While its efficacy has been attributed to early and sustained B\u00a0cell depletion, emerging evidence suggests a broader immunomodulatory profile.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>To investigate temporal dynamics of OCR-induced immune modulation in MS by analyzing pathway enrichment score changes in transcriptomic data from peripheral blood mononuclear cells (PBMCs) at early (2\u00a0weeks) and late (6\u00a0months) timepoints following treatment initiation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We analyzed publicly available microarray data (GSE228330) from PBMCs of 15 MS patients treated with OCR. Immune cell subpopulations were estimated using CIBERSORTx with the LM22 signature matrix. Gene Set Variation Analysis (GSVA) was applied to quantify immune-related pathway enrichment across three timepoints\u2014baseline, 2\u00a0weeks, and 6\u00a0months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Early effects were characterized by selective suppression of B cell-related pathways, including antigen presentation via MHC-II, B cell proliferation, and survival. These changes were accompanied by compensatory upregulation of anti-inflammatory and innate immune signaling (e.g., IL-10, monocyte chemotaxis). At 6\u00a0months, B cell pathway suppression persisted and deepened, while T cell-specific pathways (e.g., CD4+ T-cell activation and cytokine production) showed significant downregulation, indicating a delayed but substantial impact on adaptive cellular immunity. At 6\u00a0months, T\u202freg compartment was reconfigured, with overall T\u202freg transcription enhanced versus T\u202feffector cells, quiescent and thymic\u2011mature signatures reduced, and IL\u20114-induced T\u202freg program enriched.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>OCR exerts a biphasic immunomodulatory effect, with rapid direct suppression of B\u00a0cell pathways followed by delayed indirect modulation of T\u00a0cell-mediated immunity.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00415-025-13297-5","type":"journal-article","created":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T18:17:07Z","timestamp":1755368227000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["First the B cells fall, then the T cells follow: temporal immunological shift with ocrelizumab in multiple sclerosis"],"prefix":"10.1007","volume":"272","author":[{"given":"Gianmarco","family":"Abbadessa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Maida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8561-9720","authenticated-orcid":false,"given":"Simona","family":"Bonavita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Lavorgna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,16]]},"reference":[{"issue":"14","key":"13297_CR1","doi-asserted-by":"publisher","first-page":"e1999","DOI":"10.1212\/WNL.0000000000010380","volume":"95","author":"A Bar-Or","year":"2020","unstructured":"Bar-Or A, Calkwood JC, Chognot C, Evershed J, Fox EJ, Herman A, Manfrini M, McNamara J, Robertson DS, Stokmaier D, Wendt JK, Winthrop KL, Traboulsee A (2020) Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study. Neurology 95(14):e1999\u2013e2008. https:\/\/doi.org\/10.1212\/WNL.0000000000010380","journal-title":"Neurology"},{"key":"13297_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2024.578502","volume":"399","author":"CJ Gurski","year":"2025","unstructured":"Gurski CJ, Hajiyeva Z, Veltri AJ, Fenton K, O\u2019Dell S, Obeidat AZ, Dittel BN (2025) Elevated frequencies of activated memory B cells in multiple sclerosis are reset to healthy control levels after B cell depletion with Ocrelizumab. J Neuroimmunol 399:578502. https:\/\/doi.org\/10.1016\/j.jneuroim.2024.578502","journal-title":"J Neuroimmunol"},{"issue":"7","key":"13297_CR3","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1177\/13524585221147635","volume":"29","author":"G Abbadessa","year":"2023","unstructured":"Abbadessa G, Miele G, Maida E, Vanore E, Cipriano L, Coppola C, Lavorgna L, Bonavita S (2023) Immunomodulatory effects of ocrelizumab and candidate biomarkers for monitoring treatment response in multiple sclerosis. Mult Scler 29(7):779\u2013788. https:\/\/doi.org\/10.1177\/13524585221147635","journal-title":"Mult Scler"},{"key":"13297_CR4","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000940","volume":"2","author":"JI Fern\u00e1ndez-Velasco","year":"2021","unstructured":"Fern\u00e1ndez-Velasco JI, Kuhle J, Monreal E, Meca-Lallana V, Meca-Lallana J, Izquierdo G, Gasc\u00f3n-Gim\u00e9nez F, Sainz de la Maza S, Walo-Delgado PE, Maceski A, Rodr\u00edguez-Mart\u00edn E, Rold\u00e1n E, Villarrubia N, Saiz A, Blanco Y, S\u00e1nchez P, Carre\u00f3n-Guarnizo E, Aladro Y, Brieva L, \u00cd\u00f1iguez C, Gonz\u00e1lez-Su\u00e1rez I, Rodr\u00edguez de Antonio LA, Masjuan J, Costa-Frossard L, Villar LM (2021) Effect of ocrelizumab in blood leukocytes of patients with primary progressive MS. Neurol Neuroimmunol Neuroinflamm 2:e940. https:\/\/doi.org\/10.1212\/NXI.0000000000000940","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"13297_CR5","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200084","volume":"10","author":"A Mathias","year":"2023","unstructured":"Mathias A, Pantazou V, Perriot S, Canales M, Jones S, Oberholster L, Moulin M, Fenwick C, Bernard-Valnet R, Th\u00e9audin M, Pot C, Du Pasquier RA (2023) Ocrelizumab impairs the phenotype and function of memory CD8+ T cells: a 1-year longitudinal study in patients with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 10(2):e200084. https:\/\/doi.org\/10.1212\/NXI.0000000000200084","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"13297_CR6","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200250","volume":"11","author":"G Abbadessa","year":"2024","unstructured":"Abbadessa G, Lepore MT, Bruzzaniti S, Piemonte E, Miele G, Signoriello E, Perna F, De Falco C, Lus G, Matarese G, Bonavita S, Galgani M (2024) Ocrelizumab alters cytotoxic lymphocyte function while reducing EBV-specific CD8+ T-cell proliferation in patients with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 11(4):e200250. https:\/\/doi.org\/10.1212\/NXI.0000000000200250","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"13297_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L, OPERA I and OPERA II Clinical Investigators (2017) Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 376(3):221\u2013234. https:\/\/doi.org\/10.1056\/NEJMoa1601277","journal-title":"N Engl J Med"},{"issue":"3","key":"13297_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS, ORATORIO Clinical Investigators (2017) Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 376(3):209\u2013220. https:\/\/doi.org\/10.1056\/NEJMoa1606468","journal-title":"N Engl J Med"},{"issue":"4","key":"13297_CR9","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1111\/ene.14823","volume":"29","author":"G Giovannoni","year":"2022","unstructured":"Giovannoni G, Kappos L, de Seze J, Hauser SL, Overell J, Koendgen H, Manfrini M, Wang Q, Wolinsky JS (2022) Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. Eur J Neurol 29(4):1238\u20131242. https:\/\/doi.org\/10.1111\/ene.14823","journal-title":"Eur J Neurol"},{"issue":"2","key":"13297_CR10","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1007\/s00415-023-11943-4","volume":"271","author":"L Kappos","year":"2024","unstructured":"Kappos L, Traboulsee A, Li DKB, Bar-Or A, Barkhof F, Montalban X, Leppert D, Baldinotti A, Schneble HM, Koendgen H, Sauter A, Wang Q, Hauser SL (2024) Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension. J Neurol 271(2):642\u2013657. https:\/\/doi.org\/10.1007\/s00415-023-11943-4","journal-title":"J Neurol"},{"issue":"4","key":"13297_CR11","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000210142","volume":"104","author":"JJ Cerqueira","year":"2025","unstructured":"Cerqueira JJ, Berthele A, Cree BAC, Filippi M, Pardo G, Pearson OR, Traboulsee A, Ziemssen T, Vollmer T, Bernasconi C, Mandel CR, Kulyk I, Chognot C, Raposo C, Schneble HM, Thanei GA, Incera E, Havrdov\u00e1 EK (2025) Long-term treatment with ocrelizumab in patients with early-stage relapsing MS: nine-year data from the OPERA studies open-label extension. Neurology 104(4):e210142. https:\/\/doi.org\/10.1212\/WNL.0000000000210142","journal-title":"Neurology"},{"key":"13297_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1158487","volume":"14","author":"CC Fong","year":"2023","unstructured":"Fong CC, Spencer J, Howlett-Prieto Q, Feng X, Reder AT (2023) Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: gene expression and protein profiles. Front Neurol 14:1158487. https:\/\/doi.org\/10.3389\/fneur.2023.1158487","journal-title":"Front Neurol"},{"issue":"7","key":"13297_CR13","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, Khodadoust MS, Esfahani MS, Luca BA, Steiner D, Diehn M, Alizadeh AA (2019) Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol 37(7):773\u2013782. https:\/\/doi.org\/10.1038\/s41587-019-0114-2","journal-title":"Nat Biotechnol"},{"issue":"22","key":"13297_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232213759","volume":"23","author":"K Akg\u00fcn","year":"2022","unstructured":"Akg\u00fcn K, Behrens J, Schriefer D, Ziemssen T (2022) Acute effects of ocrelizumab infusion in multiple sclerosis patients. Int J Mol Sci 23(22):13759. https:\/\/doi.org\/10.3390\/ijms232213759","journal-title":"Int J Mol Sci"},{"issue":"15","key":"13297_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18158163","volume":"18","author":"G Abbadessa","year":"2021","unstructured":"Abbadessa G, Miele G, Cavalla P, Valentino P, Marfia GA, Signoriello E, Landi D, Bosa C, Vercellino M, De Martino A, Missione R, Sparaco M, Lavorgna L, Lus G, Bonavita S (2021) CD19 cell count at baseline predicts B cell repopulation at 6 and 12 months in multiple sclerosis patients treated with ocrelizumab. Int J Environ Res Public Health 18(15):8163. https:\/\/doi.org\/10.3390\/ijerph18158163","journal-title":"Int J Environ Res Public Health"},{"issue":"5","key":"13297_CR16","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.4049\/jimmunol.165.5.2458","volume":"165","author":"SR Clarke","year":"2000","unstructured":"Clarke SR, Rudensky AY (2000) Survival and homeostatic proliferation of naive peripheral CD4+ T cells in the absence of self peptide:MHC complexes. J Immunol 165(5):2458\u20132464. https:\/\/doi.org\/10.4049\/jimmunol.165.5.2458","journal-title":"J Immunol"},{"issue":"4","key":"13297_CR17","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200118","volume":"10","author":"SA Laurent","year":"2023","unstructured":"Laurent SA, Strauli NB, Eggers EL, Wu H, Michel B, Demuth S, Palanichamy A, Wilson MR, Sirota M, Hernandez RD, Cree BAC, Herman AE, von B\u00fcdingen HC (2023) Effect of ocrelizumab on B- and T-cell receptor repertoire diversity in patients with relapsing multiple sclerosis from the randomized phase III OPERA trial. Neurol Neuroimmunol Neuroinflamm 10(4):e200118. https:\/\/doi.org\/10.1212\/NXI.0000000000200118","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"11","key":"13297_CR18","doi-asserted-by":"publisher","DOI":"10.1172\/JCI182790","volume":"135","author":"J Wei","year":"2025","unstructured":"Wei J, Moon J, Yasumizu Y, Zhang L, Radassi K, Buitrago-Pocasangre N, Deerhake ME, Strauli N, Chen CW, Herman A, Pedotti R, Raposo C, Yim I, Pappalardo J, Longbrake EE, Sumida TS, Axisa PP, Hafler DA (2025) Transcriptomic profiling after B cell depletion reveals central and peripheral immune cell changes in multiple sclerosis. J Clin Invest 135(11):e182790. https:\/\/doi.org\/10.1172\/JCI182790","journal-title":"J Clin Invest"},{"key":"13297_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103740","volume":"60","author":"G Abbadessa","year":"2022","unstructured":"Abbadessa G, Maida E, Miele G, Lavorgna L, Marfia GA, Valentino P, De Martino A, Cavalla P, Bonavita S (2022) Lymphopenia in multiple sclerosis patients treated with ocrelizumab is associated with an effect on CD8 T cells. Mult Scler Relat Disord 60:103740. https:\/\/doi.org\/10.1016\/j.msard.2022.103740","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"13297_CR20","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200091","volume":"10","author":"A Garcia","year":"2023","unstructured":"Garcia A, Dugast E, Shah S, Morille J, Lebrun-Frenay C, Thouvenot E, De S\u00e8ze J, Le Page E, Vukusic S, Maurousset A, Berger E, Casez O, Labauge P, Ruet A, Raposo C, Bakdache F, Buffels R, Le Fr\u00e8re F, Nicot A, Wiertlewski S, Gourraud PA, Berthelot L, Laplaud D (2023) Immune profiling reveals the T-cell effect of Ocrelizumab in early relapsing-remitting multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 10(3):e200091. https:\/\/doi.org\/10.1212\/NXI.0000000000200091","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13297_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.116973","volume":"415","author":"V Prockl","year":"2020","unstructured":"Prockl V, Nickel FT, Utz KS, Fr\u00f6hlich K, Engelhorn T, Hilz MJ, Lee DH, Linker RA, Huhn K (2020) Real world application of ocrelizumab in multiple sclerosis: single-center experience of 128 patients. J Neurol Sci 415:116973. https:\/\/doi.org\/10.1016\/j.jns.2020.116973","journal-title":"J Neurol Sci"},{"key":"13297_CR22","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.msard.2019.01.044","volume":"30","author":"L Mayer","year":"2019","unstructured":"Mayer L, Kappos L, Racke MK, Rammohan K, Traboulsee A, Hauser SL, Julian L, K\u00f6ndgen H, Li C, Napieralski J, Zheng H, Wolinsky JS (2019) Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Mult Scler Relat Disord 30:236\u2013243. https:\/\/doi.org\/10.1016\/j.msard.2019.01.044","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"13297_CR23","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1111\/ene.15171","volume":"29","author":"P Vermersch","year":"2022","unstructured":"Vermersch P, Oreja-Guevara C, Siva A, Van Wijmeersch B, Wiendl H, Wuerfel J, Buffels R, Kadner K, Kuenzel T, Comi G, CASTING Investigators (2022) Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: a primary analysis from the phase 3b CASTING single-arm, open-label trial. Eur J Neurol 29(3):790\u2013801. https:\/\/doi.org\/10.1111\/ene.15171","journal-title":"Eur J Neurol"},{"key":"13297_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ebiom.2017.01.042","volume":"16","author":"D Baker","year":"2017","unstructured":"Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K (2017) Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis. EBioMedicine 16:41\u201350. https:\/\/doi.org\/10.1016\/j.ebiom.2017.01.042","journal-title":"EBioMedicine"},{"issue":"8","key":"13297_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy174","volume":"5","author":"DJ Epstein","year":"2018","unstructured":"Epstein DJ, Dunn J, Deresinski S (2018) Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management. Open Forum Infect Dis 5(8):ofy174. https:\/\/doi.org\/10.1093\/ofid\/ofy174","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"13297_CR26","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH, HERMES Trial Group (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358(7):676\u2013688. https:\/\/doi.org\/10.1056\/NEJMoa0706383","journal-title":"N Engl J Med"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13297-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13297-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13297-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:34:27Z","timestamp":1760524467000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13297-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,16]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["13297"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13297-5","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,16]]},"assertion":[{"value":"14 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"582"}}